Oncology

Revolution Medicines booth at ASCO 2026
Pharma

FDA greenlights RevMed’s pancreatic cancer gamechanger

Following dynamite data that earned a standing ovation at ASCO, RevMed's star Ras inhibitor daraxonrasib has been approved by the FDA.
Darren Incorvaia Aug 26, 2026 11:30am
Connection together puzzle pieces Concept of business strategy collaboration

McKesson acquires Maryland CRO for $2.25 billion

Aug 25, 2026 11:22am
Daiichi

Daiichi promotes Ken Keller to lead new commercialization unit

Aug 24, 2026 4:32am
Karyopharm

Karyopharm reports Xpovio miss, FDA filing in separate cancers

Jul 31, 2026 10:00am
India India pharma Indian pharmaceutical industry rupee pills
Favicon Fierce Biotech

How India can build on its budding innovative R&D moment: report

Jul 23, 2026 5:00am
reputation rating ranking

Roche tops cancer reputation rankings as AstraZeneca climbs back

Jul 2, 2026 6:00am
More News

FDA finds fault with Pinnacle’s photodynamic therapy videos

Jun 25, 2026 10:12am

AstraZeneca spells out a cancer screening strategy with the YMCA

Jun 25, 2026 4:30am

Obesity meds, China drive $2T in projected 2032 drug sales: report

Jun 23, 2026 9:00am

Verastem mulls options on approved asset in pancreatic cancer

Jun 17, 2026 3:00pm